15th WAA Congress at the ASFA 2014 Annual Meeting

CORPORATE PROGRAM

SAN FRANCISCO

HYATT REGENCY SAN FRANCISCO APRIL 2-5, 2014

an international educational and networking forum for professionals in the field of apheresis medicine
More than 18,000 employees in the United States

Offering diversified medicines, vaccines and innovative therapeutic solutions all over the world

Key locations in U.S. include: AZ, FL, GA, MA, MN, MO, NJ, PA, TN, WA

SANOFI: FOCUSED ON THE NEEDS OF PATIENTS

Many achievements in Sanofi’s long history have influenced the evolution of pharmaceutical science. Today, Sanofi is a global, integrated healthcare organization that finds and offers therapeutic solutions to many of the world’s most pressing health-related challenges. In collaboration with our partners, we strive to grasp the complexity of diseases while listening to patients, understanding their needs, and supporting them in many different ways. We have placed patients at the very heart of our approach.

For more information: www.sanofi.com - www.sanofi.us

CORPORATE PROGRAM

CORPORATE SUPPORTERS

ASFA and WAA wish to acknowledge the support of all of the companies and organizations who contributed generously to the 2014 ASFA & WAA Joint Conference.

KEYNOTE LEVEL SUPPORTER

TERUMO BCT
Unlocking the Potential of Blood

GOLD LEVEL SUPPORTERS

AMGEN Therakos

SILVER LEVEL SUPPORTER

SANOFI ONCOLOGY

BRONZE LEVEL SUPPORTERS

ALEXION Fenwal

SYMPOSIA SUPPORTERS

ALEXION Fenwal octapharma TERUMOBCT Therakos

AWARD SUPPORTERS

ITxM Blood Systems

United Blood Services

SAN FRANCISCO, CA • Hyatt Regency San Francisco • April 2-5, 2014
### CORPORATE PROGRAM

**PROGRAM**

**WEDNESDAY, APRIL 2, 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00AM – 11:00AM</td>
<td>Bayview A &amp; B</td>
<td><strong>CORPORATE BREAKFAST SYMPOSIUM</strong>&lt;br&gt;Supported by Fresenius Kabi&lt;br&gt;Implementation of a New Therapeutic Apheresis Technology&lt;br&gt;This session will focus on a review of data and implementation experiences with a new therapeutic apheresis platform, the Fenwal Amicus.&lt;br&gt;<strong>Amicus MNC: A Blood Center’s Experience in Implementing a New Platform for MNC Collection</strong>&lt;br&gt;Christina Anderson, RN, BSN, HP (ASCP), Carter BloodCare&lt;br&gt;<strong>Amicus MNC: A Hospital’s Experience in Implementing a New Platform for MNC Collection</strong>&lt;br&gt;Phillip DeChristopher, MD, PhD, Loyola University Medical Center&lt;br&gt;<strong>Amicus TPE: A Hospital’s Recent Experience with Amicus as a New Platform for TPE</strong>&lt;br&gt;Ed Burgstaler, MT, ASCP(HP)</td>
</tr>
<tr>
<td>9:45AM – 10:15AM</td>
<td>Grand A</td>
<td><strong>APHERESIS REVIEW SESSION</strong>&lt;br&gt;<strong>COFFEE BREAK</strong>&lt;br&gt;Supported by Fresenius Kabi</td>
</tr>
<tr>
<td>12:00PM – 3:00PM</td>
<td>Bayview A &amp; B</td>
<td><strong>CORPORATE LUNCH SYMPOSIUM</strong>&lt;br&gt;Supported by Terumo BCT&lt;br&gt;Join your colleagues and industry leaders at Terumo BCT’s Educational Symposium. The symposium will focus on the latest Spectra Optia® Apheresis System protocols released in the U.S: mononuclear cell collection, red blood cell exchange and granulocyte collection. An interactive question and answer session will follow each presentation. Audience participation is encouraged.</td>
</tr>
<tr>
<td>3:30PM – 3:45PM</td>
<td>Grand A</td>
<td><strong>APHERESIS REVIEW SESSION</strong>&lt;br&gt;<strong>COFFEE BREAK</strong>&lt;br&gt;Supported by Fresenius Kabi</td>
</tr>
</tbody>
</table>
**CORPORATE PROGRAM**

**WEDNESDAY, APRIL 2, 2014**

**WELCOME RECEPTION IN EXHIBIT HALL**

Supported by Terumo BCT

Terumo BCT is proud to sponsor the ASFA and WAA Joint Conference Welcome Reception in the conference exhibit hall. Please join us for cocktails, hors d’oeuvres, and to network with your colleagues. Visit the Terumo BCT booth and learn more about how we are advancing the delivery of therapeutic apheresis.

6:00PM – 8:00PM
Grand B & C

**CORPORATE DINNER SYMPOSIUM**

Supported by Octapharma

Octaplas™ (Pooled plasma (Human), solvent/detergent treated solution for intravenous infusion) – A virally inactivated plasma for transfusion: Product overview and European experience.

This dinner symposium will provide a clinical overview of Octaplas™, a solvent-detergent treated, pooled plasma product new to the US market. A review of 2 principal mechanisms for reducing the risk of viral transmission (plasma pooling and S/D treatment) will be provided, as well as a review of mechanisms for reducing the risk of transfusion-related adverse events such as TRALI and allergic reactions. Further, a review of 10+ years of clinical experience with Octaplas™ in St. Anna Kinderspital, Vienna, Austria will also be provided.

The symposium will be hosted by Octapharma with presentations being made by: Dr. Volker Witt, MD from Vienna, Austria and Dr. Andrea Neisser-Svaes, PhD with Octapharma; Hoboken, NJ

7:30PM – 10:30PM
Bayview A & B

**THURSDAY, APRIL 3, 2014**

**BREAKFAST WITH THE EXPERT I**

(Pre-registration with ASFA Required)

Supported by Therakos

7:00AM – 8:15AM
Bayview A & B

**CONTINENTAL BREAKFAST**

Supported by Sanofi Oncology

7:00AM – 8:30AM
Grand Foyer
### CORPORATE PROGRAM

#### THURSDAY, APRIL 3, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15AM – 10:45AM</td>
<td>COFFEE BREAK</td>
<td>Grand B &amp; C</td>
<td>Fenwal (A Fresenius Kabi Company)</td>
</tr>
<tr>
<td>12:30PM – 1:15PM</td>
<td>NETWORKING LUNCH</td>
<td>Bayview A &amp; B</td>
<td>SANOFI ONCOLOGY</td>
</tr>
<tr>
<td>3:30PM – 4:00PM</td>
<td>COFFEE BREAK</td>
<td>Grand B &amp; C</td>
<td>Fenwal (A Fresenius Kabi Company)</td>
</tr>
<tr>
<td>7:30PM – 10:30PM</td>
<td>CORPORATE DINNER SYMPOSIUM</td>
<td>Bayview A &amp; B</td>
<td>ALEXION (Alexion Pharmaceuticals)</td>
</tr>
</tbody>
</table>

**Thrombotic Microangiopathies: Advances in aHUS Disease and Diagnosis**

Systemic TMA is a process of widespread thrombi and inflammation in the small blood vessels of vital organs throughout the body. The multiple thrombi and inflammation occur throughout the body, affecting the brain, kidneys, heart, organs of the gastrointestinal system, and lungs. The clinical presentation of aHUS can have significant clinical overlap (signs and symptoms) with other diseases, some of which are caused by systemic TMA such as TTP and STEC-HUS.

Presented by: **Bruce Berger, MD**, Associate Professor of Medicine, Case Western Reserve University, Cleveland, OH

Educational Objectives:
1. A typical Hemolytic Uremic Syndrome (aHUS): Overview of Disease and Diagnosis
2. Role of Complement in aHUS
3. Differential diagnosis for TMAs: aHUS, TTP, and STEC-HUS
FRIDAY, APRIL 4, 2014

7:00AM – 8:30AM  
Bayview A & B  
**BREAKFAST WITH THE EXPERT II**  
(Pre-registration with ASFA Required)  
Supported by Therakos

7:00AM – 8:30AM  
Grand B & C  
**CONTINENTAL BREAKFAST**  
Supported by Sanofi Oncology

10:15AM – 10:45AM  
Grand B & C  
**COFFEE BREAK**  
Supported by Alexion Pharmaceuticals

3:45PM – 4:15PM  
Grand Foyer  
**COFFEE BREAK**  
Supported by Alexion Pharmaceuticals

6:00PM – 9:00PM  
Bayview A & B  
**CORPORATE DINNER SYMPOSIUM**  
Supported by Therakos

Running a successful Photopheresis center; establishing value within your institution

Keynote Speaker: **Marisa Marques, MD**, Medical Director UAB Apheresis Service, Division of Laboratory Medicine, University of Alabama at Birmingham

Objectives:
- To provide an overview of both the components and benefits of a successful Photopheresis Program.
- To discuss important topics such as building referral networks, creating operational efficiencies, and establishing the Photopheresis Program as a value driver for your institution.
- To discuss placing an appropriate focus on health economics and patient outcomes as the foundation for decision making.

Followed by a Q&A with a Panel of Experts from successful Photopheresis Programs

SATURDAY, APRIL 5, 2014

7:00AM – 8:30AM  
Bayview A & B  
**BREAKFAST WITH THE EXPERT III**  
(Pre-registration with ASFA Required)  
Supported by Therakos
EXHIBIT LIST AND FLOOR PLAN

EXHIBITOR LIST

<table>
<thead>
<tr>
<th>EXHIBITOR LIST</th>
<th>BOOTH #</th>
</tr>
</thead>
<tbody>
<tr>
<td>3M Health Care</td>
<td>11</td>
</tr>
<tr>
<td>Infection Prevention Division</td>
<td></td>
</tr>
<tr>
<td>Alexion Pharmaceuticals</td>
<td>13</td>
</tr>
<tr>
<td>American Society for Apheresis (ASFA)</td>
<td>7</td>
</tr>
<tr>
<td>Angiodynamics</td>
<td>8</td>
</tr>
<tr>
<td>Asahi Kasei Medical America, Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Fresenius Kabi</td>
<td>1</td>
</tr>
<tr>
<td>Fresenius Medical Care Apheresis Services</td>
<td>14</td>
</tr>
<tr>
<td>Healthcare – ID</td>
<td>16</td>
</tr>
<tr>
<td>Kaneka Pharma America, LLC</td>
<td>17</td>
</tr>
<tr>
<td>Octapharma</td>
<td>4</td>
</tr>
<tr>
<td>Terumo BCT</td>
<td>3</td>
</tr>
<tr>
<td>Therakos</td>
<td>2</td>
</tr>
<tr>
<td>UC San Diego</td>
<td>12</td>
</tr>
<tr>
<td>University of Virginia</td>
<td>15</td>
</tr>
<tr>
<td>World Apheresis Association (WAA)</td>
<td>10</td>
</tr>
</tbody>
</table>

EXHIBIT FLOOR PLAN

EXHIBIT HOURS

Exhibits are located in Grand B & C

- Wednesday, April 2, 2014 6:00pm – 8:00pm
- Thursday, April 3, 2014 10:00am – 8:00pm
- Friday, April 4, 2014 7:00am – 10:45am
EXHIBITOR DIRECTORY

3M HEALTH CARE – INFECTION PREVENTION DIVISION  BOOTH 11

Arizant Healthcare Inc., a 3M Company, pioneered the concept of forced-air patient warming with the introduction of Bair Hugger™ therapy in 1987. Today, our groundbreaking lineup of temperature management products includes the Bair Paws™ system and the Ranger™ fluid warming systems.

ALEXION PHARMACEUTICALS  BOOTH 13

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition and has developed and markets a treatment for patients with PNH and aHUS, two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. The treatment is currently approved in more than 40 countries for the treatment of PNH, and in the United States and the European Union for the treatment of aHUS. Alexion is evaluating other potential indications for its marketed drug and is developing four other highly innovative biotechnology product candidates, which are being investigated across additional severe and ultra-rare disorders.

AMERICAN SOCIETY FOR APHERESIS (ASFA)  BOOTH 7

Asfa is an organization of physicians, scientists, and allied health professionals whose mission is to advance apheresis medicine for patients, donors and practitioners through education, evidence-based practice, research and advocacy. ASFA represents a broad range of professionals involved in: donor apheresis, apheresis in transplantation & therapeutic apheresis. ASFA welcomes you to San Francisco!

ANGIODYNAMICS  BOOTH 8

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.

ASAHI KASEI MEDICAL AMERICA INC.  BOOTH 9

Asahi Kasei Medical, a pioneer in blood purification, proudly introduces our Therapeutic Apheresis
Division. This division provides innovative therapies for intractable diseases by extending the frontiers of medical devices and systems for extracorporeal treatment, such as plasmapheresis. In the dialysis market Asahi Kasei Medical offers REXEED™ series dialyzers. REXEED™, the high performance polysulfone dialyzer, offers unparalleled performance and patient safety, and is offered in multiple sizes including 2.5 square meters.

**FRESENIUS KABI**

Fresenius Kabi, is a pioneer and global leader in the development of products that improve the safety and availability of blood. Fenwal products help shape the practice of transfusion medicine, making life-saving blood therapies available to the medical professionals and patients worldwide who rely on them.

**FRESENIUS MEDICAL CARE APHERESIS SERVICES**

Fresenius Medical Care’s Therapeutic Apheresis Program provides high quality patient care, while substantially reducing the cost of these services to medical centers. We provide a fully equipped apheresis program to include state of the art equipment, specially trained registered nurses and Medical Director oversight. We provide: Plasmapheresis, Leukocytapheresis, Thrombocytapheresis, Erythrocytapheresis, LDL Apheresis, and Photopheresis. Treating: Thrombotic Thrombocytopenic Purpura (TTP), Sickle Cell Disease, Guillain-Barre Syndrome (GBS); Myasthenia Gravis; Autoimmune Polyneuropathies: Pulmonary Renal Syndrome; Systemic Lupus Erythematosus.

**HEALTHCARE-ID**

Healthcare-ID's Donor-ID Web™ automates documentation at fixed and mobile collection sites and interfaces to most BCDMS/BECS. Modules: Registration, Health History, CASI, Internet CASI, Physical Exam, Daily QC, Phlebotomy, Shipping, Survey, Donor Adverse Reaction (AABB biovigilance).

**KANEKA PHARMA AMERICA, LLC**

Kaneka is the developer and manufacturer of the Liposorber System, which is an FDA approved LDL-Apheresis system that is used in hospitals, clinics, and physician offices across the US for the treatment of patients who cannot meet their LDL cholesterol goals despite maximum diet and drug therapy.

**OCTAPHARMA**

Headquartered in Lachen, Switzerland, Octapharma AG is one of the world’s largest human protein products manufacturers and has been committed to patient care and medical innovation for nearly 30 years.
With a broad and expanding pipeline, Octapharma’s core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including intravenous immune globulin and von Willebrand Factor/Coagulation Factor VIII Complex. Octapharma employs over 4,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit www.octapharma.com or www.wilateusa.com.

Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers. Terumo BCT—Unlocking the Potential of Blood.

Therakos is a leader in advancing the science of immune cell therapies. Therakos markets the world's only approved integrated systems for extracorporeal photopheresis which have a demonstrated track record of efficacy and safety and have been used globally for more than 25 years.

UC San Diego Health System is San Diego’s only academic health system and is comprised of hospitals in San Diego, including UC San Diego Medical Center in Hillcrest, and UC San Diego Thornton Hospital, Moores Cancer Center, Shiley Eye Center, Sulpizio Cardiovascular Center and Jacobs Medical Center (opening in 2016) in La Jolla. UC San Diego Health System has one of the largest therapeutic apheresis programs in the United States. Directed by David Ward, MD, an international leader in the field, the Apheresis Program is dedicated to the highest level of patient care.

UC San Diego Health System Apheresis Program offers:

- The only photopheresis and LDL apheresis in San Diego County.
- Outpatient plasmapheresis, photopheresis, LDL apheresis, red cell exchange apheresis, white cell reduction apheresis, platelet reduction apheresis
and hematopoietic stem cell harvest apheresis.
- The largest hematopoietic stem cell (HSC) collection facility in San Diego County.
- Onsite physician presence during treatment.
- Latest state-of-the-art technology.

The goal of the Office of Continuing Medical Education is to create opportunities for learning that will enhance and expand the skills and knowledge of health care professionals and improve the quality of health care delivery in Virginia, surrounding states, the nation and the world. Continuing medical education (CME) is part of the learning continuum initiated in undergraduate education, intensified during graduate medical education and maintained throughout the life of the health care professional. CME links this lifelong learning process to the research, teaching, patient care, and public service missions of the School of Medicine and the goals of the Virginia Generalist Initiative.

**UNIVERSITY OF VIRGINIA**  
**BOOTH 15**

[University of Virginia logo]

The World Apheresis Association is a professional organization for national and international professional societies devoted to the scientific, medical, practical, technical, administrative, and educational aspects of apheresis. WAA welcomes you to the 15th WAA Congress at the ASFA 2014 Annual Conference!

**WORLD APHERESIS ASSOCIATION (WAA)**  
**BOOTH 10**

[World Apheresis Association logo]
CORPORATE PROGRAM

Notes
Propose a Session  Recommend a Speaker
Submit an Abstract
Register to Attend  Reserve Your Exhibit Space
Plan Your Marketing and Advertising
Book Your Corporate Symposium or Tutorial

PROGRAM FORMAT:

- Scientific Symposia
- Education Sessions
- Oral and Poster Abstract Presentations
- Interactive Case Studies and Discussions
- Networking Receptions
- Committee Meetings
- Corporate Symposia and Tutorials
- Exhibit Hall
- Graduate Medical Education Forum
- Apheresis Review Session
Please visit us at booth #2

For 30 years, we have been developing life-saving therapies from human proteins.

Octapharma is proud to support the ASFA and WAA 2014 Joint Conference.
Please visit us at Booth #4 to learn more.

Get to know Octapharma better

- Fully committed to manufacturing high-quality immunoglobulins to help improve patient quality of life
- Two state-of-the-art FDA-licensed facilities for fully integrated manufacturing; from raw materials to final product
- A broad and expanding product pipeline

Like to learn more?
Visit www.octapharma.com
ADVANCING APHERESIS

Terumo BCT is committed to advancing therapeutic apheresis and cell collections. Through our collaboration with customers, we are enabling the best possible procedures today, increasing adoption of established uses, developing next-generation technologies and identifying new uses.

SEE HOW WE CAN ADVANCE APHERESIS TOGETHER:
COME TO BOOTH 3
VISIT TERUMOBCT.COM/ASF